Clinical Trial

. 2021 Jan 7;16(1):e0245142.

doi: 10.1371/journal.pone.0245142. eCollection 2021.

Personality dimensions of patients can change during the course of parkinson's disease

Mathilde Boussac¹, Christophe Arbus², Julia Dupouy³, Estelle Harroch⁴, Vanessa Rousseau⁴, Aurélie Croiset⁵, Fabienne Ory-Magne^{1

4}, Olivier Rascol^{1

4}, Caroline Moreau⁶, Anne-Sophie Rolland⁶, David Maltête^{7

8}, Tiphaine Rouaud⁹, Mylène Meyer¹⁰, Sophie Drapier^{11

12}, Bruno Giordana¹³, Mathieu Anheim^{14

15

16}, Elodie Hainque¹⁷, Béchir Jarraya^{18

19}, Isabelle Benatru²⁰, Nicolas Auzou²¹, Lhaouas Belamri²², Mélissa Tir²³, Ana-Raquel Marques²⁴, Stephane Thobois^{25

26

27}, Alexandre Eusebio²⁸, Jean Christophe Corvol¹⁷, David Devos⁶, Christine Brefel-Courbon^{1

4}; PREDI-STIM study group

Affiliations

¹ Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
² Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
³ Department of Neurology, Hospital of Avignon, Avignon, France.
⁴ Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
⁵ CERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France.
⁶ Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
⁷ Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
⁸ Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U1239, NS-PARK/FCRIN Network, Mont-Saint-Aignan, France.
⁹ Clinique Neurologique, Hôpital Guillaume et René Laennec, NS-PARK/FCRIN Network, Boulevard Jacques Monod, Nantes, France.
¹⁰ Neurology Department, Nancy University Hospital, Nancy, France.
¹¹ Behavior and Basal Ganglia Research Unit (EA 4712), University of Rennes 1, Rennes, France.
¹² Department of Neurology, Rennes University Hospital, NS-PARK/FCRIN Network, Rennes, France.
¹³ Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.
¹⁴ Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
¹⁵ Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
¹⁶ Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, NS-PARK/FCRIN Network, Strasbourg, France.
¹⁷ Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.
¹⁸ Pôle Neurosciences, Foch Hospital, Suresnes, France.
¹⁹ Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, France.
²⁰ Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France.
²¹ CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France.
²² Hôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France.
²³ Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France.
²⁴ Neurology Department, Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, NS-PARK/FCRIN Network, Clermont-Ferrand, France.
²⁵ Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Sud Charles Mérieux, Lyon, France.
²⁶ CNRS, Institut des Sciences Cognitives, UMR 5229, Bron, France.
²⁷ Centre Expert Parkinson, Hôpital Neurologique "Pierre Wertheimer", Hospices Civils de Lyon, NS-PARK/FCRIN Network, Lyon, France.
²⁸ Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.

PMID: 33411732
PMCID: PMC7790271
DOI: 10.1371/journal.pone.0245142

Clinical Trial

Personality dimensions of patients can change during the course of parkinson's disease

Mathilde Boussac et al. PLoS One. 2021.

. 2021 Jan 7;16(1):e0245142.

doi: 10.1371/journal.pone.0245142. eCollection 2021.

Authors

Affiliations

¹ Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
² Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
³ Department of Neurology, Hospital of Avignon, Avignon, France.
⁴ Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
⁵ CERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France.
⁶ Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
⁷ Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
⁸ Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U1239, NS-PARK/FCRIN Network, Mont-Saint-Aignan, France.
⁹ Clinique Neurologique, Hôpital Guillaume et René Laennec, NS-PARK/FCRIN Network, Boulevard Jacques Monod, Nantes, France.
¹⁰ Neurology Department, Nancy University Hospital, Nancy, France.
¹¹ Behavior and Basal Ganglia Research Unit (EA 4712), University of Rennes 1, Rennes, France.
¹² Department of Neurology, Rennes University Hospital, NS-PARK/FCRIN Network, Rennes, France.
¹³ Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.
¹⁴ Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
¹⁵ Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
¹⁶ Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, NS-PARK/FCRIN Network, Strasbourg, France.
¹⁷ Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.
¹⁸ Pôle Neurosciences, Foch Hospital, Suresnes, France.
¹⁹ Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, France.
²⁰ Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France.
²¹ CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France.
²² Hôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France.
²³ Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France.
²⁴ Neurology Department, Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, NS-PARK/FCRIN Network, Clermont-Ferrand, France.
²⁵ Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Sud Charles Mérieux, Lyon, France.
²⁶ CNRS, Institut des Sciences Cognitives, UMR 5229, Bron, France.
²⁷ Centre Expert Parkinson, Hôpital Neurologique "Pierre Wertheimer", Hospices Civils de Lyon, NS-PARK/FCRIN Network, Lyon, France.
²⁸ Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.

PMID: 33411732
PMCID: PMC7790271
DOI: 10.1371/journal.pone.0245142

Abstract

Background: Studies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PD patients with motor fluctuations and compare them to a normative population and other PD populations.

Methods: All PD patients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations).

Results: Most personality dimensions of our 333 included PD patients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PD patients with motor fluctuations.

Conclusions: During the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments.

Trial registration: ClinicalTrials.gov NCT02360683.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

1. Santangelo G, Garramone F, Baiano C, D’Iorio A, Piscopo F, Raimo S, et al. Personality and Parkinson’s disease: A meta-analysis. Parkinsonism. 2018. - PubMed
1. Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, et al. Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM). J Park Dis. 2020. Jan 1;10(3):1057–66. 10.3233/JPD-191903 - DOI - PubMed
1. Pélissolo A, Lépine JP. Normative data and factor structure of the Temperament and Character Inventory (TCI) in the French version. Psychiatry Res. 2000. Apr 24;94(1):67–76. 10.1016/s0165-1781(00)00127-x - DOI - PubMed
1. Dupouy J. Personnalité Et Maladie De Parkinson Idiopathique: À Propos D’Une Revue De La Littérature Et De Deux Études Expérimentales. Toulouse; 2014.
1. Kaasinen V, Nurmi E, Bergman J, Eskola O, Solin O, Sonninen P, et al. Personality traits and brain dopaminergic function in Parkinson’s disease. In: Proceedings of the National Academy of Sciences of the United States of America. 2001. p. 13272–13277. 10.1073/pnas.231313198 - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Personality dimensions of patients can change during the course of parkinson's disease

Affiliations

Personality dimensions of patients can change during the course of parkinson's disease

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical